What is the impact of a country-wide scale-up in antiviral therapy on the characteristics and sustained viral response rates of patients treated for hepatitis C?

Scott A. McDonald; Hamish A. Innes; Peter C. Hayes; John F. Dillon; Peter R. Mills; David J. Goldberg; Stephen Barclay; Sam Allen; Ray Fox; Andrew Fraser; Nicholas Kennedy; Diptendu Bhattacharyya; Sharon J. Hutchinson

doi:10.1016/j.jhep.2014.08.046

What is the impact of a country-wide scale-up in antiviral therapy on the characteristics and sustained viral response rates of patients treated for hepatitis C?

Scott A. McDonald (Lead / Corresponding author)
, Hamish A. Innes
, Peter C. Hayes
, John F. Dillon
, Peter R. Mills
, David J. Goldberg
, Stephen Barclay
, Sam Allen
, Ray Fox
, Andrew Fraser
, Nicholas Kennedy
, Diptendu Bhattacharyya
, Sharon J. Hutchinson

Research output: Contribution to journal › Article › peer-review

8 Citations (Scopus)

Abstract

The global burden associated with hepatitis C virus (HCV) infection has prompted a scale-up of antiviral therapy. Hitherto, no data existed on the impact of scaling-up on the characteristics of treated populations or on sustained viral response (SVR) rates. We assessed the country-wide scale-up of antiviral therapy in Scotland, a country which nationally monitors uptake of and response to HCV treatment METHODS: Data for patients initiated on combined pegylated interferon and ribavirin therapy at 13 specialist HCV clinics in 2001-2010 were extracted from the Scottish HCV Clinical Database (n=3895). Patient characteristics included age, genotype, PWID (people who inject drugs) status, prison referral, and diagnosed cirrhosis. Temporal trends in covariates and adjusted effects on SVR were examined via mixed-effects regression.

Original language	English
Pages (from-to)	262-268
Number of pages	7
Journal	Journal of Hepatology
Volume	62
Issue number	2
DOIs	https://doi.org/10.1016/j.jhep.2014.08.046
Publication status	Published - Feb 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Antiviral therapy
Hepatitis C virus
Pegylated interferon
Sustained viral response

ASJC Scopus subject areas

Hepatology

Access to Document

10.1016/j.jhep.2014.08.046

Cite this

McDonald, S. A., Innes, H. A., Hayes, P. C., Dillon, J. F., Mills, P. R., Goldberg, D. J., Barclay, S., Allen, S., Fox, R., Fraser, A., Kennedy, N., Bhattacharyya, D., & Hutchinson, S. J. (2015). What is the impact of a country-wide scale-up in antiviral therapy on the characteristics and sustained viral response rates of patients treated for hepatitis C? Journal of Hepatology, 62(2), 262-268. https://doi.org/10.1016/j.jhep.2014.08.046

@article{25d81c01b2a94ebcb46f0308e7b54db5,

title = "What is the impact of a country-wide scale-up in antiviral therapy on the characteristics and sustained viral response rates of patients treated for hepatitis C?",

abstract = "The global burden associated with hepatitis C virus (HCV) infection has prompted a scale-up of antiviral therapy. Hitherto, no data existed on the impact of scaling-up on the characteristics of treated populations or on sustained viral response (SVR) rates. We assessed the country-wide scale-up of antiviral therapy in Scotland, a country which nationally monitors uptake of and response to HCV treatment METHODS: Data for patients initiated on combined pegylated interferon and ribavirin therapy at 13 specialist HCV clinics in 2001-2010 were extracted from the Scottish HCV Clinical Database (n=3895). Patient characteristics included age, genotype, PWID (people who inject drugs) status, prison referral, and diagnosed cirrhosis. Temporal trends in covariates and adjusted effects on SVR were examined via mixed-effects regression.",

keywords = "Antiviral therapy, Hepatitis C virus, Pegylated interferon, Sustained viral response",

author = "McDonald, \{Scott A.\} and Innes, \{Hamish A.\} and Hayes, \{Peter C.\} and Dillon, \{John F.\} and Mills, \{Peter R.\} and Goldberg, \{David J.\} and Stephen Barclay and Sam Allen and Ray Fox and Andrew Fraser and Nicholas Kennedy and Diptendu Bhattacharyya and Hutchinson, \{Sharon J.\}",

note = "Copyright {\textcopyright} 2014. Published by Elsevier B.V.",

year = "2015",

month = feb,

doi = "10.1016/j.jhep.2014.08.046",

language = "English",

volume = "62",

pages = "262--268",

journal = "Journal of Hepatology",

issn = "0168-8278",

publisher = "Elsevier",

number = "2",

}